Article

Peptide CIGB-552 has a synergistic effect on CFTR-F508del combined with Elexacaftor/Tezacaftor/Ivacaftor

2024-09-23

Abstract excerpt

Cystic fibrosis is an autosomal recessive disease in which mutations in the CFTR gene lead to a reduced life expectancy in carriers, partly due to the rapid loss of respiratory functions. CFTR-F508del is the most frequent mutation, leading to a mislocalized and non-functional CFTR protein. The tri-therapy Elexacaftor/Tezacaftor/Ivacaftor is now given to patients carrying CFTR-F508del mutation, but some biological...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 42383407-cf5e-5f3a-ad62-4b7fc291f2aa
DOI: 10.22541/au.172708942.28055581/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Peptide CIGB-552 has a synergistic effect on CFTR-F508del combined with Elexacaftor/Tezacaftor/IvacaftorDOI 10.22541/au.172708942.28055581/v1Read

Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.Semantic proximity Read

Esc peptides and derivatives potentiate the activity of CFTR with gating defects and display antipseudomonal activity in cystic fibrosis-like lung diseaseSemantic proximity Read

The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.Semantic proximity Read

The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.Semantic proximity Read

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Semantic proximity Read

Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor.Semantic proximity Read

Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background.Semantic proximity Read

F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Semantic proximity Read

Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.Semantic proximity Read

Current development of CFTR potentiators in the last decade.Semantic proximity Read

CFTR structures bound to ETI components predict rare mutation response to modulator combinationsSemantic proximity Read

In Silico Evaluation of Lumacaftor for Cystic FibrosisSemantic proximity Read